As researchers keep looking for ways to deescalate treatment in HER2-positive breast cancer, a trial from China looked at a chemotherapy-free regimen with endocrine therapy, a CDK4/6 inhibitor, and ...

The firm will test gedatolisib as a first-line treatment in patients with HR-positive, HER2-negative advanced breast cancer who are endocrine therapy resistant.

No one wants to hear the words: "You have cancer." But about 1 in 8 American women will learn they have breast cancer, according to the Centers for Disease Control and Prevention. "Breast ...

A reproductive endocrinologist was found liable in a medical malpractice lawsuit after failing to diagnose a patient with ...

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer ...

On August 7, 2025, Puma Biotechnology will host a conference call/webcast to review its financial results for the second ...

A local breast cancer survivor is now sharing her story, urging patients like her, to be confident in their plan, by receiving a “second opinion” from a professional.

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.